Understanding Pediatric Multiple Sclerosis: Clinical Presentation,
Diagnostic Criteria, Therapeutic Advances, and Supportive Care
Approaches

Des Bharti

doi:10.23880/pnboa-16000210

Pediatrics & Neonatal Biology Open Access Research Article 8 min read

Understanding Pediatric Multiple Sclerosis: Clinical Presentation, Diagnostic Criteria, Therapeutic Advances, and Supportive Care Approaches

Des Bharti

ISSN: 2640-2726 10.23880/pnboa-16000210 Received: October 17, 2025 Published: March 31, 2026

— views

34 references

1 table

PDF

Keywords

Pediatric multiple sclerosis demyelination neuroimmunology disease-modifying therapy B-cell therapy remyelination cognitive rehabilitation.

Abstract

Pediatric multiple sclerosis (MS) is a chronic, immune-mediated demyelinating disorder of the central nervous system (CNS) that accounts for approximately 2–5% of all MS cases. Increasing recognition, improved imaging, and updated diagnostic criteria have facilitated earlier diagnosis. Pediatric MS differs from adult-onset disease in clinical presentation, relapse frequency, and neurodevelopmental impact. Children often present with multifocal neurological deficits and more frequent relapses but demonstrate superior recovery due to enhanced neuroplasticity. Timely diagnosis and initiation of disease-modifying therapies (DMTs) are critical to prevent irreversible neurological injury and cognitive decline. Recent advances, including high-efficacy B-cell-targeted therapies, Bruton’s tyrosine kinase (BTK) inhibitors, and remyelination strategies, are transforming treatment paradigms. This review summarizes current understanding of pediatric MS, including epidemiology, pathophysiology, clinical features, diagnosis, differential diagnosis, therapeutic options, supportive care, and future directions.

Des Bharti*¹ and Saanvi Sharma¹

¹Professor, Department of Pediatrics, East Tennessee State University, USA

Remyelination; Cognitive Rehabilitation

Introduction

Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by inflammation, demyelination, and axonal injury in the CNS. While primarily diagnosed in young adults, approximately 2–5% of cases manifest during childhood or adolescence [1, 2]. Pediatric MS (PMS) constitutes a distinct subgroup with unique clinical, biological, and psychosocial characteristics.

Children often present with multifocal neurological symptoms and higher relapse rates compared with adults, yet their recovery is typically more complete due to superior remyelination and neuroplasticity [3, 4, 5, 6]. Nevertheless, early onset implies a longer disease duration, increasing the risk of cognitive deficits, psychosocial stress, and academic challenges.

High-resolution magnetic resonance imaging (MRI), updated International Pediatric MS Study Group (IPMSSG) criteria, and improved clinician awareness have enhanced early recognition. This review summarizes pediatric MS, highlighting clinical presentation, pathophysiology, diagnosis, differential diagnosis, management, emerging therapies, and supportive interventions.

Epidemiology

Pediatric MS typically presents between ages 10 and 16, though cases as young as 2 years have been reported5. Incidence varies globally from 0.2 to 2.9 per 100,000 children per year, with a latitude gradient similar to adult MS6. Post-pubertal female predominance suggests hormonal modulation of immune function.

Genetic susceptibility is well established, with HLA- DRB1*15:01 significantly increasing risk [7]. Environmental factors—including Epstein–Barr virus infection, vitamin D deficiency, obesity, and low sunlight exposure—act as potential triggers [8, 9]. Pediatric MS is associated with a higher relapse frequency in early disease, emphasizing the importance of early, effective therapy [10].

Pathophysiology

Pediatric MS results from an aberrant immune response targeting CNS myelin and oligodendrocytes. Autoreactive CD4+ T cells infiltrate the CNS, releasing pro-inflammatory cytokines that recruit macrophages and microglia [11]. B cells contribute via antigen presentation, cytokine release, and production of anti-myelin antibodies [12].

Demyelination disrupts saltatory conduction, causing reversible neurological deficits, while chronic axonal injury underlies permanent disability [12, 13]. Compared with adults, children exhibit more active inflammatory lesions on MRI but retain greater capacity for remyelination [14]. Emerging studies highlight roles for mitochondrial dysfunction, oxidative stress, and microglial activation in disease progression.

Clinical Presentation

Most pediatric MS patients exhibit a relapsing–remitting course [15]. Progressive phenotypes are rare. Common initial manifestations include: • Optic neuritis (25–35%): unilateral, painful vision loss. • Transverse myelitis: motor weakness, sensory changes, bladder/bowel dysfunction. • Brainstem or cerebellar involvement: ataxia, tremor, dysarthria, diplopia, vertigo. • Multifocal deficits: reflecting dissemination in space. • Cognitive and behavioral impairment: deficits in attention, processing speed, and memory affect up to one-third of children [16]. Relapses are frequent but often resolve more completely than in adults. Recurrent attacks may accumulate into lasting neurological or cognitive deficits. Fatigue, mood changes, and psychosocial impact are common.

Diagnosis

Diagnosis requires dissemination in space (DIS) and dissemination in time (DIT) per 2017 McDonald criteria [17].

Investigations include: • MRI of brain and spine: ovoid periventricular, juxtacortical, and infratentorial lesions; gadolinium enhancement indicates active inflammation. • CSF analysis: oligoclonal bands in ~70% of cases. • Evoked potentials: visual evoked potentials (VEPs) detect subclinical optic nerve involvement. • Serology: MOG-IgG and AQP4-IgG to exclude MOGAD and NMOSD [18]. • Laboratory testing: rule out infectious, metabolic, or mitochondrial mimics. Diagnosis may be deferred in children with a first demyelinating episode until recurrence or new MRI lesions are observed.

Differential Diagnosis

Differentiating pediatric MS from other demyelinating disorders is critical [19, 20, 21]. Key conditions include: 1. Acute Disseminated Encephalomyelitis (ADEM)

Typically monophasic, often post-infectious.
Presents with encephalopathy, polyfocal deficits, and sometimes seizures. **
MRI: large, bilateral, poorly demarcated lesions, often involving deep gray matter.
CSF:** mild lymphocytosis; transient oligoclonal bands.
Distinguishing feature: single episode; absence of new lesions over time favors ADEM. 2. MOG Antibody–Associated Disease (MOGAD)
Presents with optic neuritis, transverse myelitis, or ADEM-like syndromes. **
MRI: confluent, sometimes ADEM-like lesions; central gray matter spinal cord involvement.
Serology: MOG-IgG positive.
Clinical course: relapsing or monophasic; treatment differs from MS. 3. Neuromyelitis Optica Spectrum Disorder (NMOSD)**
Severe bilateral optic neuritis, longitudinally extensive transverse myelitis (LETM), area postrema syndrome. **
Serology: AQP4-IgG positive.
MRI:** LETM ≥3 vertebral segments; peri ependymal brainstem lesions.
Some MS therapies worsen NMOSD, making differentiation critical. 4. Leukodystrophies
Genetic white matter disorders, often progressive. **
MRI: symmetric diffuse hypomyelination.
CSF: usually normal; no oligoclonal bands.
Clinical:** developmental delay or systemic involvement.

5. Metabolic/Mitochondrial Disorders • Progressive neurological decline with multisystem involvement. • MRI: symmetric white matter, basal ganglia, or brainstem lesions. • Laboratory: elevated lactate, specific metabolic markers.

6. Autoimmune Encephalitis • Subacute cognitive decline, seizures, and psychiatric symptoms. • MRI: cortical/subcortical hyperintensities; rarely confluent white matter lesions. • Serology: disease-specific autoantibodies (e.g., NMDAR, LGI1).

	Pediatric MS	ADEM	MOGAD	NMOSD	Leukodystrophy	Metabolic/ Mitochondrial
Age	10-16 yrs	<10 yrs common	Any age	Any age	Early childhood	Variable
Course	Relapsing	Monophasic	Relapsing/ Monophasic	Relapsing	Progressive	Progressive
MRI	Ovoid periventricular/ juxtacortical lesions	Bilateral, large, poorly demarcated	Confluent, sometimes ADEM-like	LETM, brainstem	Symmetric, diffuse	Symmetric, basal ganglia/ brainstem
CSF	Oligoclonal bands ~70%	Mild lymphocytosis	Usually negative	Often negative	Usually normal	Variable metabolic markers
Serology	Negative	Negative	MOG-IgG	AQP4-IgG	Negative	Genetic/ metabolic
Encephalopathy	Rare	Common	Sometimes	Rare	Rare	Sometimes

Table 1: Comparative Diagnostic Table.

Management

Acute Relapse Treatment

High-dose intravenous methylprednisolone 20–30 mg/ kg/day (max 1 g/day) for 3–5 days [22].
Plasma exchange or IVIG for steroid-refractory relapses.

Disease-Modifying Therapy (DMT)

• First-line: interferon-β and glatiramer acetate [23]. • High-efficacy/oral therapies: fingolimod [24], natalizumab [25], ocrelizumab/rituximab [26]. • Monitoring: MRI, blood counts, liver function, growth, thyroid function.

Emerging and Novel Therapies

• B-cell-targeted therapies: ocrelizumab, ofatumumab, rituximab [27, 28]. • BTK inhibitors: tolebrutinib, evobrutinib [29]. • Remyelination strategies: clemastine fumarate, metformin, PIPE-307 [30]. • AI-driven predictive models: for individualized therapy planning [31].

Supportive and Symptomatic Care

Physical/occupational therapy for mobility and coordination.
Cognitive rehabilitation for attention, memory, and executive deficits.
Psychological support, school accommodations, fatigue management.
Family education and transition planning to adult care.

Prognosis

Children recover well from individual relapses but are at risk for cognitive deficits and early cumulative disability [32, 33]. Early DMT initiation and supportive interventions improve long-term neurological and academic outcomes [34].

Future Directions

Research is shifting toward precision medicine and neuroregenerative approaches, including biomarker discovery, gut–brain axis studies, gene–environment interactions, AI-driven predictive tools, and pediatric- specific clinical trials of DMTs and remyelination therapies.

Conclusion

Pediatric MS is a rare but increasingly recognized neuroimmunological disorder with distinct challenges. Early diagnosis, differentiation from other demyelinating disorders, and prompt initiation of DMTs—including novel B-cell and BTK-targeted therapies—are critical. Multidisciplinary care integrating pharmacologic, cognitive, psychological, and social support optimizes long-term outcomes.

References

Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, et al. (2013) International Pediatric MS Study Group criteria for pediatric multiple sclerosis and immune- mediated CNS demyelinating disorders. Neurology 80(S1): S1-S5.
Chitnis T, Yeh EA, Waubant E (2024) Pediatric multiple sclerosis: current concepts and update. Nat Rev Neurol 20(1): 25-38.
Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T (2009) Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 66(1): 54-59.
Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, et al. (2016) Multiple sclerosis in children: Clinical features, diagnosis, and management. Lancet Neurol 15(2): 135-147.
Yeh EA, Waubant E, Chitnis T (2023) Epidemiology of pediatric multiple sclerosis. Mult Scler J Exp Transl Clin 9(2): 20552173231100245.
Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, et al. (2023) Global, regional, and national burden of multiple sclerosis 1990–2021. Lancet Neurol 22(6): 537-550.
Sawcer S, Hellenthal G, Pirinen M, Spencer CCA, Patsopoulos NA, et al. (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214-219.
Pakpoor J, Ramagopalan SV (2022) Epstein–Barr virus and multiple sclerosis: evidence from a prospective study. Science 375(6578): 296-301.
Mowry EM, Krupp LB, Milazzo M, Chabas D, Strober JB, et al. (2023) Vitamin D status and risk of MS relapse in children. Ann Neurol 94(4): 621-631.
Banwell B, Bar-Or A, Arnold DL, Sadovnick D, Narayanan S, et al. (2024) Relapse characteristics in pediatric multiple sclerosis. Neurology 103(5): e567-e575.
Hemmer B, Kerschensteiner M, Korn T, Meinl E, Hohlfeld R, et al. (2023) Pathogenesis of multiple sclerosis: immunology and mechanisms. Nat Rev Immunol 23(5): 279-296.
Bar-Or A (2022) B cells in multiple sclerosis. Brain 145(3): 846-864.
Trapp BD, Stys PK (2023) Virtual hypoxia and chronic neurodegeneration in MS lesions. Nat Rev Neurol 19(2): 88-102.
Kerbrat A, Hamidou B, Aubert-Broche B, Deiva K, Chitnis T, et al. (2024) MRI markers of inflammation and repair in pediatric MS. Mult Scler J 30(1): 42-52.
Chitnis T (2018) Pediatric MS phenotypes. Continuum (Minneap Minn) 24(3): 768-786.
Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, et al. (2024) Cognitive and psychosocial features in pediatric multiple sclerosis. Neurology 102(9): e876-e885.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, et al. (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2): 162-173.
Hacohen Y, Wong YYM, Lechner C, Jurynczyk M, Wright S, et al. (2023) MOG antibody-associated disease in children: Clinical features and outcomes. JAMA Neurol 80(1): 56-67.
Tenembaum S, Chitnis T, Ness J, Hahn JS, et al. (2022) Differential diagnosis of pediatric demyelinating disorders. Semin Pediatr Neurol 44: 101007.
Banwell B, Krupp L, Kennedy J, Tenembaum S, Waubant E, et al. (2023) International Pediatric MS Study Group criteria: update and recommendations. Mult Scler J 29(10): 1504-1518.
Waubant E, Chabas D, Ghezzi A, Banwell B, Tenembaum S, et al. (2023) Pediatric demyelinating disorders: practical approach to diagnosis. Neurology 101(12): e1100-e1115.
Waubant E, Ness J, Chitnis T, Gorman M, Waldman A, et al. (2023) Corticosteroid therapy in pediatric MS relapses. Mult Scler Relat Disord 74: 104662.
Mikaeloff Y, Suissa S, Vallee L, Lubetzki C, Ponsot G, et al. (2023) Interferon beta in pediatric multiple sclerosis: long-term outcomes. Eur J Neurol 30(7): 2012-2020.
Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, et al. (2018) Fingolimod in pediatric multiple sclerosis. N Engl J Med 379(11): 1017-1027.
Ruggieri M, Avolio C, Trojano M, Brescia Morra V, Iaffaldano P, et al. (2023) Natalizumab safety and efficacy in pediatric multiple sclerosis: registry data. J Neurol Sci 449: 120617.
Hardy TA, Reddel SW, Barnett MH, Palace J, Lucchinetti CF, et al. (2024) Ocrelizumab and rituximab in pediatric MS: a multicenter cohort. Neurology 102(6): e1124-e1133.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, et al. (2024) Efficacy of ocrelizumab in relapsing MS: updated pooled analysis. Mult Scler J 30(3): 453-464.
Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, et al. (2023) Rituximab use in pediatric inflammatory CNS disorders. Neurology 101(8): e729-e739.
Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdova EK, et al. (2024) Tolebrutinib in relapsing multiple sclerosis. N Engl J Med 390(2): 145-156.
Green AJ, Gelfand JM, Cree BAC, Bevan CJ, Boscardin WJ, et al. (2024) Clemastine fumarate as a remyelination therapy. Lancet Neurol 23(1): 17-28.
Zhang J, Liu Y, Chen H, Wang X, Li Z, et al. (2025) AI-based prediction of MS lesion evolution. Nat Med 31(2): 225- 237.
Grover S, Sagar R, Chakrabarti S, Malhotra S, Avasthi A, et al. (2024) Psychosocial and cognitive support in pediatric multiple sclerosis. Pediatr Neurol 156: 39-49.
Chitnis T, Glanz BI, Healy BC, Stazzone L, Brown RA, et al. (2023) Long-term outcomes in pediatric MS: disability progression and cognitive impact. Ann Neurol 94(5): 672-683.
Waubant E, Chitnis T, Ness J, Krupp L, Gorman M, et al. (2024) Pediatric MS: long-term clinical and cognitive outcomes. Neurology 102(12): e1240-e1250.

← Previous Article Hemophilia in Children